HUMDF (Hua Medicine) Short-Term Debt: $4.35 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HUMDF Hua Medicine HUMDF
44 GF Score
Price $0.34
GF Value $1.16
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Hua Medicine Short-Term Debt?

Hua Medicine HUMDF 44 Short-Term Debt is $4.35 Mil as of Dec. 2025. GuruFocus rates HUMDF with a GF Score™ of 44/100 and a GF Value™ of $1.16 (Possible Value Trap). The stock has 6 warning signs investors should review.

Hua Medicine's Short-Term Debt for the quarter that ended in Dec. 2025 was $4.35 Mil.

Hua Medicine's quarterly Short-Term Debt declined from Dec. 2024 ($13.50 Mil) to Jun. 2025 ($6.55 Mil) and declined from Jun. 2025 ($6.55 Mil) to Dec. 2025 ($4.35 Mil).

Hua Medicine's annual Short-Term Debt increased from Dec. 2023 ($2.41 Mil) to Dec. 2024 ($13.50 Mil) but then declined from Dec. 2024 ($13.50 Mil) to Dec. 2025 ($4.35 Mil).

Hua Medicine Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Hua Medicine Short-Term Debt Related Terms

Hua Medicine Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Hua Medicine's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hua Medicine Short-Term Debt Chart

Hua Medicine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 4.87 2.41 13.50 4.35

Hua Medicine Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.41 9.07 13.50 6.55 4.35
HUMDF
44GF Score
Hua Medicine HUMDF
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $4.35 Mil mean?
Hua Medicine (HUMDF) has a Short-Term Debt of $4.35 Mil as of Dec. 2025.
Is Hua Medicine's Short-Term Debt too high?
Hua Medicine's current Short-Term Debt is $4.35 Mil. Overall, Hua Medicine has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hua Medicine's Short-Term Debt compare to ZTS and UTHR?
Hua Medicine's Short-Term Debt of $4.35 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Hua Medicine's current Short-Term Debt is $4.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hua Medicine stock overvalued right now?
Based on GuruFocus' analysis, Hua Medicine (HUMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.16, compared to a current price of $0.34 — trading 70.7% below its estimated fair value. The current Short-Term Debt is $4.35 Mil. Hua Medicine's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Hua Medicine (HUMDF), the current Short-Term Debt is $4.35 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hua Medicine (HUMDF) Overvalued in 2026?

Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued. The current stock price of $0.34 is trading 70.7% below its estimated GF Value™ of $1.16. GuruFocus considers Hua Medicine to be Possible Value Trap.

Key valuation signals for HUMDF:

  • Short-Term Debt: $4.35 Mil
  • GF Value™: $1.16 vs. price of $0.34 (70.7% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the HUMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hua Medicine Business Description

Other Exchanges 02552:Hong Kong
Address Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
44GF Score

Get the complete analysis for HUMDF

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price
$1.16
GF Value